You are here

  • Home
  • Archive
  • Volume 11, Issue 9
  • Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis

Authors

  • Nian Liu Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Mingjie Yan Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Qian Tao Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Jie Wu Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Jing Chen Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Xiang Chen Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Cong Peng Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaFurong Laboratory, Central South University, Changsha, Hunan, ChinaHunan Key Laboratory of Skin Cancer and Psoriasis, Human Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, Hunan, ChinaNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles

Citation

Liu N, Yan M, Tao Q, et al
Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis
Journal for ImmunoTherapy of Cancer 2023;11:e007146. doi: 10.1136/jitc-2023-007146
Online issue publication 
December 06, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.